The initial engagement of host cells by pathogens is often mediated by glycan structures presented on the cell surface. Various components of the glycocalyx can be targeted by pathogens for adhesion to facilitate infection. Glycans also play integral roles in the modulation of the host immune response to infection. Therefore, understanding the parameters that define glycan interactions with both pathogens and the various components of the host immune system can aid in the development of strategies to prevent, interrupt, or manage infection. Glycomaterials provide a unique and powerful tool with which to interrogate the compositional and functional complexity of the glycocalyx. The objective of this review is to highlight some key contributions from this area of research in deciphering the mechanisms of pathogenesis and the associated host response.
PietersRJThe role of carbohydrates in bacterial infections. In: WangBBoonsG-J (eds). Carbohydrate recognition: biological problems, methods, and applications, 1st ed. Hoboken, NJ: John Wiley & Sons, Inc., 2011. Chapter 4.
9.
AudfrayAVarrotAImbertyA. Bacteria love our sugars: interaction between soluble lectins and human fucosylated glycans, structures, thermodynamics and design of competing glycocompounds. Comptes Rendus Chimie2013; 16: 482–90.
CummingsRDTurcoSParasidic infections. In: VarkiACummingsRDEskoJDFreezeHHStanleyPBertozziCRHartGWEtzlerME (eds). Essentials of Glycobiology, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2009. Chapter 40.
12.
SinnisPCoppiA. A long and winding road: the Plasmodium sporozoite’s journey in the mammalian host. Parasitol Int2007; 56: 171–8.
13.
ImaiMKawaokaY. The role of receptor binding specificity in interspecies transmission of influenza viruses. Curr Opin Virol2012; 2: 160–7.
14.
StevensJBlixtOPaulsonJCWilsonIA. Glycan microarray technologies: tools to survey host specificity of influenza viruses. Nat Rev Microbiol2006; 4: 857–64.
15.
SuzukiY. Sialobiology of influenza molecular mechanism of host range variation of influenza viruses. Biol Pharm Bull2005; 28: 399–408.
16.
RogersGNPaulsonJCDanielsRSSkehelJJWilsonIAWileyDC. Single amino acid substitutions in influenza haemagglutinin change receptor binding specificity. Nature1983; 304: 76–8.
17.
SuttonTCFinchCShaoHAngelMChenHCapuaICattoliGMonneIPerezDR. Airborne transmission of highly pathogenic H7N1 influenza in ferrets. J Virol2014; 88: 6623–35.
18.
ZhangHde VriesRPTzarumNZhuXYuWMcBrideRPaulsonJCWilsonIA. A human-infecting H10N8 influenza virus retains a strong preference for avian-type receptors. Cell Host Microbe2015; 17: 377–84.
19.
XuRde VriesRPZhuXNycholatCMMcBrideRYuWPaulsonJCWilsonIA. Preferential recognition of avian-like receptors in human influenza A H7N9 viruses. Science2013; 342: 1230–5.
RamanRTharakaramanKShriverZJayaramanASasisekharanVSasisekharanR. Glycan receptor specificity as a useful tool for characterization and surveillance of influenza A virus. Trends Microbiol2014; 22: 632–41.
22.
WaltherTKaramanskaRChanRWYChanMCWJiaNAirGHoptonCWongMPDellAMalik PeirisJSHaslamSMNichollsJM. Glycomic analysis of human respiratory tract tissues and correlation with influenza virus infection. PLoS Pathog2013; 9: e1003223–e1003223.
23.
RillahanCDPaulsonJC. Glycan microarrays for decoding the glycome. Annu Rev Biochem2011; 80: 797–823.
DengLChenXVarkiA. Exploration of sialic acid diversity and biology using sialoglycan microarrays. Biopolymers2013; 99: 650–65.
27.
Padler-KaravaniVSongXYuHHurtado-ZiolaNHuangSMuthanaSChokhawalaHAChengJVerhagenALangereisMAKleeneRSchachnerMde GrootRJLasanajakYMatsudaHSchwabRChenXSmithDFCummingsRDVarkiA. Cross-comparison of protein recognition of sialic acid diversity on two novel sialoglycan microarrays. J Biol Chem2012; 287: 22593–608.
BranderhorstHMRuijtenbeekRLiskampRMJPietersRJ. Multivalent carbohydrate recognition on a glycodendrimer-functionalized flow-through chip. ChemBioChem2008; 9: 1836–44.
34.
Parera PeraNBranderhorstHMKooijRMaierhoferCvan der KaadenMLiskampRMJWittmanVRuijtenbeekRPietersRJ. Rapid screening of lectins for multivalency effects with a glycodendrimer microarray. ChemBioChem2010; 11: 1896–904.
35.
ZhangYGildersleeveJC. General procedure for the synthesis of neoglycoproteins and immobilization on epoxide-modified glass slides. Methods Mol Biol2012; 808: 155–65.
36.
NovoaAEierhoffTTopinJVarrotABarluengaSImbertyARömerWWinssingerN. A LecA ligand identified from a galactoside-conjugate array inhibits host cell invasion by Pseudomonas aeruginosa. Angew Chemie Int Ed Engl2014; 53: 8885–9.
NarlaSNSunX-L. Immobilized sialyloligo-macroligand and its protein binding specificity. Biomacromolecules2012; 13: 1675–82.
39.
HuangMLCohenMFisherCJSchooleyRTGagneuxPGodulaK. Determination of receptor specificities for whole influenza viruses using multivalent glycan arrays. Chem Commun2015; 51: 5326–9.
40.
MammenMChoiS-KWhitesidesGM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed Engl1998; 37: 2754–94.
41.
DisneyMDSeebergerPH. The use of carbohydrate microarrays to study carbohydrate-cell interactions and to detect pathogens. Chem Biol2004; 11: 1701–7.
42.
SotoGEHultgrenSJ. Bacterial adhesions: common themes and variation in architecture and assembly. J Bacteriol1999; 181: 1059–71.
43.
BarthKACoullerezGNilssonLMCastelliRSeebergerPHVogelVTextorM. An engineered mannoside presenting platform: Escherichia coli adhesion under static and dynamic conditions. Adv Funct Mater2008; 18: 1459–69.
44.
ZhuX-YHoltzBWangYWangL-XOrndorffPEGuoA. Quantitative glycomics from fluidic glycan microarrays. J Am Chem Soc2009; 131: 13646–50.
45.
NilssonLMThomasWETrintchinaEVogelVSokurenkoEV. Catch bond-mediated adhesion without a shear threshold: trimannose versus monomannose interactions with the FimH adhesin of Escherichia coli. J Biol Chem2006; 281: 16656–63.
46.
GaunitzSLiuJNilssonAKarlssonNHolgerssonJ. Avian influenza H5 hemagglutinin binds with high avidity to sialic acid on different O-linked core structures on mucin-type fusion proteins. Glycoconj J2014; 31: 145–59.
47.
ShenLWangYLinC-ILiuH-WGuoAZhuX-Y. Membrane environment can enhance the interaction of glycan binding protein to cell surface glycan receptors. ACS Chem Biol2014; 9: 1877–84.
48.
SpevakWNagyJOCharychDHSchaeferMEGibertJHBednarskiMD. Polymerized liposomes containing C-glycosides of sialic acid: potent inhibitors of influenza virus in vitro infectivity. J Am Chem Soc1993; 115: 1146–7.
49.
GamianAChomikMLaferriereGARoyR. Inhibition of influenza A virus hemagglutinin and induction of interferon by synthetic sialylated glycoconjugates. Can J Microbiol1991; 37: 233–7.
50.
NagyJOWangPGilbertJHSchaeferMEHillTGCallstromMRBednarskiMD. Carbohydrate materials bearing neuraminidase-resistant C-glycosides of sialic acid strongly inhibit the in vitro infectivity of influenza virus. J Med Chem1992; 35: 4501–2.
Kingergy-WoodJEWilliamsKWSigalGBWhitesidesGM. The agglutination of erythrocytes by influenza virus is strongly inhibited by liposomes incorporating an analog of sialyl gangliosides. J Am Chem Soc1992; 114: 7303–5.
54.
SpaltensteinAWhitesidesGM. Polyacrylamides bearing pendant α-sialoside groups strongly inhibit agglutination of erythrocytes by influenza virus. J Am Chem Soc1991; 113: 686–7.
55.
MammenMDahmannGWhitesidesGM. Effective inhibitors of hemagglutination by influenza virus synthesized from polymers having active ester groups: Insight into mechanism of inhibition. J Med Chem1995; 38: 4179–90.
56.
LeesWJSpaltensteinAKingery-WoodJEWhitesidesGM. Polyacrylamides bearing pendant α-sialoside groups strongly inhibit agglutination of erythrocytes by influenza A virus: multivalency and steric stabilization of particulate biological systems. J Med Chem1994; 37: 3419–33.
57.
SparksMAWilliamsKWWhitesidesGM. Neuraminidase-resistant hemagglutination inhibitors: acrylamide copolymers containing a C-glycoside of N-acetylneuraminic acid. J Med Chem1993; 36: 778–83.
58.
SigalGBMammenMDahmannGWhitesidesGM. Polyacrylamides bearing pendant α-sialoside groups strongly inhibit agglutination of erythrocytes by influenza virus—the strong inhibition reflects enhanced binding through cooperative polyvalent interactions. J Am Chem Soc1996; 118: 3789–800.
59.
MatrosovichMKlenkH-D. Natural and synthetic sialic acid-containing inhibitors of influenza virus receptor binding. Rev Med Virol2003; 13: 85–97.
PappISiebenCSissonALKostkaJBöttcherCLudwigKHerrmannAHaagR. Inhibition of influenza virus activity by multivalent glycoarchitectures with matched sizes. ChemBioChem2011; 12: 887–95.
62.
WaldmannMJirmannRHoelscherKWienkeMNiemeyerFCRehdersDMeyersB. A nanomolar multivalent ligand as entry inhibitor of the hemagglutinin of avian influenza. J Am Chem Soc2014; 136: 783–8.
63.
HidariKIMurataTYoshidaKTakahashiYMinamijimaY-HMiwaYAdachiSOgataMUsuiTSuzukiYSuzukiT. Chemoenzymatic synthesis, characterization, and application of glycopolymers carrying lactosamine repeats as entry inhibitors against influenza virus infection. Glycobiology2008; 18: 779–88.
64.
PappISiebenCLudwigKRoskampMBöttcher C, SchlectSHerrmannA. Inhibition of influenza A virus infection by multivalent sialic acid functionalized gold particles. Small2010; 6: 2900–6.
65.
TollasSBereczkiIBorbasABattaGVanderlindenENaesensLHerczeghP. Synthesis of a cluster-forming sialylthio-D-galactose fullerene conjugate and evaluation of its interaction with influenza virus hemagglutinin and neuraminidase. Bioorg Med Chem Lett2014; 24: 2420–3.
66.
ZevgitiSZabalaJGDarjiADietrichUPanou-PomonisESakarellos-DaitsiotisM. Sialic acid and sialyl-lactose glycol-conjugates: design, synthesis and binding assays to lectins and swine influenza H1N1 virus. J Pept Sci2012; 18: 52–8.
67.
CohenMZhangX-QSenaatiHChenH-WVarkiNMSchooleyRTGagneux. Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase. Virol J2013; 10: 321–321.
68.
LielegOLielegCBloomJBuckCBRibbeckK. Mucin biopolymers as broad-spectrum antiviral agents. Biomacromolecules2012; 13: 1724–32.
69.
SharonN. Carbohydrates as future anti-adhesion drugs for infectious diseases. Biochim Biophys Acta2006; 1760: 527–37.
70.
ImbertyAChabreYMRoyR. Glycomimetics and glycodendrimers as high affinity microbial anti-adhesins. Chem Eur J2008; 14: 7490–9.
DondoniAMarraA. Calixarene and calixresorcarene glycosides: their synthesis and biological applications. Chem Rev2010; 110: 4949−77.
75.
CecioniSLalorRBlanchardBPralyJPImbertyAMatthewsSEVidalS. Achieving high affinity towards a bacterial lectin through multivalent topological isomers of calix[4]arene glycoconjugate. Chem Eur J2009; 15: 13232−40.
76.
CecioniSPralyJPMatthewsSEWimmerováMImbertyAVidalS. Rational design and synthesis of optimized glycoclusters for multivalent lectin carbohydrate interactions: influence of the linker arm. Chem Eur J2012; 18: 6250−63.
77.
BoukerbAMRoussetAGalanosNMéarJ-BThépautMGrandjeanTGillonECecioniSAbderrahmenCFaureKRedelbergerDKipnisEDesseinRHavetSDarbladeBMatthewsSEde BentzmannSGuéryBCournoyerBImbertyAVidalS. Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection. J Med Chem2014; 57: 10275–89.
78.
ReynoldsMMarradiMImbertyAPenadésSPérezS. Multivalent gold glycoclusters: high affinity molecular recognition by bacterial lectin PA-IL. Chemistry2012; 18: 4264–73.
79.
VincentSPBuffetKNierengartenIImbertyANierengartenJF. Biologically active hetero-glycoclusters constructed on a pillar[5]arene-containing [2]rotaxane scaffold. Chem Eur J2016; 4: 88–92.
80.
RoyRShiaoTCRittenhouse-OlsonK. Glycodendrimers—versatile tools for nanotechnology. BJPS2013; 49: 85–108.
81.
BergmannMMichaudGVisiniRJinXGillonEStockerAImbertyADarbreTReymondJ-L. Multivalency effects on Pseudomonas aeruginosa biofilm inhibition and dispersal by glycopeptide dendrimers targeting lectin LecA. Org Biomol Chem2016; 14: 138–48.
82.
MichaudGVisiniRBergmannMSalernoGBoscoRGillonERichichiBNativiCImbertyAStockerADarbreTReymondJ-L. Overcoming antibiotic resistance in Pseudomonas aeruginosa biofilms using glycopeptide dendrimers. Chem Sci2016; 7: 166–82.
BuffetKGillonEHollerMNierengartenJFImbertyAVincentSP. Fucofullerenes as tight ligands of RSL and LecB, two bacterial lectins. Org Biomol Chem2015; 13: 6482–92.
85.
CaldaraMFriedlanderRSKavanaughNLAizenbergJFosterKRRibbeckK. Mucin biopolymers prevent bacterial aggregation by retaining cells in the free-swimming state. Curr Biol2012; 22: 2325–30.
86.
YanXSivignonAYamakawaNCrepetATraveletCBorsaliRDumychTLiZBilyyRDeniaudDFleuryEBarnichNDarfeuille-MichaudAGouinSGBouckaertJBernardJ. Glycopolymers as antiadhesives of E. coli strains inducing inflammatory bowel diseases. Biomacromolecules2015; 16: 1827–36.
87.
LeeD-WKimTParkI-SHuangZLeeM. Multivalent nanofibers of a controlled length: regulation of bacterial cell agglutination. J Am Chem Soc2012; 134: 14722–25.
88.
RyuJ-HLeeELimY-BLeeM. Carbohydrate-coated supramolecular structures: transformation of nanofibers into spherical micelles triggered by guest encapsulation. J Am Chem Soc2007; 129: 4808–14.
89.
BransonTRTurnbullWB. Bacterial toxin inhibitors based on multivalent scaffolds. Chem Soc Rev2013; 42: 4613–22.
90.
PolizzottiBDKiickKL. Effects of polymer structure on the inhibition of cholera toxin by linear polypeptide-based glycopolymers. Biomacromolecules2006; 7: 483–90.
91.
JoostenJAFLoimarantaVAppeldoornCCMHaatajaSEl MaateFALiskampRMJFinneJPietersPJ. Inhibition of Streptococcus suis adhesion by dendritic galabiose compounds at low nanomolar concentration. J Med Chem2004; 47: 6499–6508.
92.
BranderhorstHMKooijRSalminenAJongeneelLHArnuschCJLiskampRMFinneJPietersRJ. Synthesis of multivalent Streptococcus suis adhesion inhibitors by enzymatic cleavage of polygalacturonic acid and ‘click’ conjugation. Org Biomol Chem2008; 6: 1425–34.
93.
RavdinJIStanleyPMurphyCFPetriWAJr. Characterization of cell surface carbohydrate receptors for Entamoeba histolytica adherence lectin. Infect Immun1989; 57: 2179–86.
94.
AdlerPWoodsSJLeeYCLeeRTPetriWAJrSchnaarRL. High affinity binding of the Entamoeba histolytica lectin to polyvalent N-acetylgalactosaminides. J Biol Chem1995; 270: 5164–71.
95.
JanewayCAJrMedzhitovR. Innate immune recognition. Annu Rev Immunol2002; 20: 197–216.
96.
SpiegelDA. Synthetic immunology to engineer human immunity. Nat Chem Biol2010; 6: 871–2.
97.
GeeringBFusseneggerM. Synthetic immunology: modulating the human immune system. Trends Biotechnol2015; 33: 65–79.
98.
YuKLaiBFFoleyJHKrisingerMJConwayEMKizzhakkedathuJN. Modulation of complement activation and amplification on nanoparticle surfaces by glycopolymer conformation and chemistry. ACS Nano2014; 8: 7687–703.
99.
GengJMantovaniGTaoLNicolasJChenGWallisRMitchellDAJohnsonBREvansSDHaddletonDM. Site-directed conjugation of “clicked” glycopolymers to form glycoprotein mimics: binding to mammalian lectin and induction of immunological function. J Am Chem Soc2007; 129: 15156–63.
100.
Rubin-BejeranoIAbeijonCMagnelliPGrisafiRFinkGR. Phagocytosis by human neutrophils is stimulated by a unique fungal cell wall component. Cell Host Microbe2007; 2: 55–67.
101.
SchlesingerLSHullSRKaufmanTM. Binding of the terminal mannosyl units of lipoarabinomannan from a virulent strain of Mycobacterium tuberculosis to human macrophages. J Immunol1994; 152: 4070–9.
102.
MahlaRSReddyMCPrasadDVKumarH. Sweeten PAMPs: role of sugar complexed PAMPs in innate immunity and vaccine biology. Front Immunol2013; 4: 248–248.
103.
HotalingNACummingsRDRatnerDMBabenseeJE. Molecular factors in dendritic cell responses to adsorbed glycoconjugates. Biomaterials2014; 35: 5862–74.
CummingsRDMcEverRPC-type lectins. In: VarkiACummingsRDEskoJDFreezeHHStanleyPBertozziCRHartGWEtzlerME (eds). Essentials of Glycobiology, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2009. Chapter 31.
107.
VargaNSutkeviciuteIRibeiro-VianaRBerziARamdasiRDaghettiAVelorettiGAmaraAClericiMRojoJFieschiFBernardiA. A multivalent inhibitor of the DC-SIGN dependent uptake of HIV-1 and Dengue virus. Biomaterials2014; 35: 4175–84.
108.
WangJZhangYWeiJZhangXZhangBZhuZZouWWangYMouZNiBWuY. Lewis X oligosaccharides targeting to DC-SIGN enhanced antigen-specific immune response. Immunology2007; 121: 174–82.
109.
MunozASigwaltDIllescasBMLuczkowiakJRodriguez-PerezLNierengartenIHollerMRemyJ-SBuffetKVincentSPRojoJDelgadoRNierengartenJ-FMartinN. Synthesis of giant globular multivalent glycofullerenes as potent inhibitors in a model of Ebola virus infection. Nat Chem2016; 8: 50–7.
110.
AngataTNycholatCMMacauleyMS. Therapeutic targeting of Siglecs using antibody- and glycan-based approaches. Trends Pharmacol Sci2015; 36: 645–60.
111.
RaziNVarkiA. Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes. Proc Natl Acad Sci USA1998; 95: 7469–74.
112.
CollinsBEBlixtOHanSDuongBLiHNathanJKBovinNPaulsonJC. High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells. J Immunol2006; 177: 2994–3003.
113.
RillahanCDSchwartzEMcBrideRFokinVVPaulsonJC. Click and pick: identification of sialoside analogues for siglec-based cell targeting. Angew Chem Int Ed Engl2012; 51: 11014–8.
114.
RillahanCDSchwartzERademacherCMcBrideRRangarajanJFokinVVPaulsonJC. On-chip synthesis and screening of a sialoside library yields a high affinity ligand for Siglec-7. ACS Chem Biol2013; 8: 1417–22.
115.
ChenWCKawasakiNNycholatCMHanSPilotteJCrockerPRPaulsonJC. Antigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin/CD169. PLoS One2012; 7: e39039–e39039.
116.
CourtneyAHBennettNRZwickDBHudonJKiesslingLL. Synthetic antigens reveal dynamics of BCR endocytosis during inhibitory signaling. ACS Chem Biol2014; 9: 202–10.
117.
HudakJECanhamSMBertozziCR. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoinvasion. Nat Chem Biol2014; 10: 69–75.
118.
SandersWJGordonEJDwirOBeckPJAlonRKiesslingLL. Inhibition of L-selectin-mediated leukocyte rolling by synthetic glycoprotein mimics. J Biol Chem1999; 274: 5271–8.
AstronomoRDBurtonDR. Carbohydrate vaccines: developing sweet solutions to sticky situations. Nat Rev Drug Discov2010; 9: 308–24.
121.
AveryOTGoebelWF. Chemo-immunological studies on conjugated carbohydrate-proteins: V. The immunological specificity of an antigen prepared by combining the capsular polysaccharide of type III Pneumococcus with foreign protein. J Exp Med1931; 54: 437–47.
122.
TrkolaAPurtscherMMusterTBallaunCBuchacherASullivanNSrinivasanKSodroskiJMooreJPKatingerH. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus. J Virol1996; 70: 1100–8.
123.
CalareseDAScanlanCNZwickMBDeechongkitSMimuraYKunertRZhuPWormaldMRStanfieldRLRouxKHKellyJWRuddPMDwekRAKatingerHBurtonDRWilsonIA. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science2003; 300: 2065–71.
124.
HoriyaSMacPhersonISKraussIJ. Recent strategies targeting HIV glycans in vaccine design. Nat Chem Biol2014; 10: 990–9.
125.
WangL-X. Synthetic carbohydrate antigens for HIV vaccine design. Curr Opin Chem Biol2013; 17: 997–1005.
126.
KraussIJJoyceJGFinnefrockACSongHCDudkinVYGengXWarrenJDChastainMShiverJWDanishefskySJ. Fully synthetic carbohydrate HIV antigens designed on the logic of the 2G12 antibody. J Am Chem Soc2007; 129: 11042–4.
127.
WangJLiHZouGWangLX. Novel template-assembled oligosaccharide clusters as epitope mimics for HIV-neutralizing antibody 2G12. Design, synthesis, and antibody binding study. Org Biomol Chem2007; 5: 1529–40.
128.
WangSKLiangPHAstronomoRDHsuTLHsiehSLBurtonDRWongCH. Targeting the carbohydrates on HIV-1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci USA2008; 105: 3690–5.
129.
DooresKJFultonZHongVPatelMKScanlanCNWormaldMRFinnMGBurtonDRWilsonIADavisBG. A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity. Proc Natl Acad Sci USA2010; 107: 17107–12.
130.
AstronomoRDKaltgradEUditAKWangSKDooresKJHuangCYPantophletRPaulsonJCWongCHFinnMGBurtonDR. Defining criteria for oligomannose immunosense for HIV using icosahedral virus capsid scaffolds. Chem Biol2010; 17: 357–70.
131.
NovoaAWinssingerN. DNA display of glycoconjugates to emulate oligomeric interactions of glycans. Beilstein J Org Chem2015; 11: 707–19.
132.
GorskaKHuangK-TChaloinOWinssingerN. DNA-templated homo- and heterodimerization of peptide nucleic acid encoded oligosaccharides that mimick the carbohydrate epitope of HIV. Angew Chem Int Ed2009; 48: 7695–700.
133.
Ribero-VianaRGarcía-VallejoJJColladoDPérez-InestrosaEBloemKvan KooykYRojoJ. BODIPY-labeled DC-SIGN-targeting glycodendrons efficiently internalize and route to lysosomes in human dendritic cells. Biomacromolecules2012; 13: 3209–19.
134.
CiobanuMHuangK-TDaguerJ-PBarluengaSChaloinOSchaefferEMuellerCGMitchellDAWinssingerN. Selection of a synthetic glycan oligomer from a library of DNA-templated fragments against DC-SIGN and inhibition of HIV gp120 binding to dendritic cells. Chem Commun2011; 47: 9321–3.
135.
ZhangQCollinsJAnastasakiAWallisRMitchellDABecerCRHaddletonDM. Sequence-controlled multi-block glycopolymers to inhibit DC-SIGN-gp120 binding. Angew Chem Int Ed2013; 52: 4435–9.
136.
NordlyPAggerEMAndersenPNielsenHMFogedC. Incorporation of the TLR4 agonist monophosporyl lipid A into the bilayer of DDA/TDB liposomes: physicochemical characterization and induction of CD8+ T-cell responses in vivo. Pharm Res2011; 28: 553–62.
137.
AggerEMRosenkrandsIHansenJBrahimiKVandahlBSAagaardCWerninghausKKirschningCLangRChristensenDTheisenMFollmannFAndersenP. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One2008; 3: e3116–e3116.
138.
GramGJKarlssonIAggerEMAndersenPFomsgaardA. A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice. PLoS One2009; 4: e6950–e6950.
139.
FomsgaardAKarlssonIGramGSchouCTangSBangPKromannIAndersenPAndreasenLV. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. Vaccine2011; 29: 7067–74.
140.
DavidsenJRosenkrandsIChristensenDVangalaAKirbyDPerrieYAggerEMAndersenP. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)—a novel adjuvant inducing both strong CMI and antibody responses. Biochem Biophys Acta2005; 1718: 22–31.
141.
TeramotoNSachnivalaNDShibataM. Trehalose and trehalose-based polymers for environmentally benign, biocompatible and bioactive materials. Molecules2008; 13: 1773–1816.
142.
ManciniRJLeeJMaynardHD. Trehalose glycopolymers for stabilization of protein conjugates to environmental stressors. J Am Chem Soc2012; 134: 8474–9.
143.
TorosantucciABromuroCChianiPDe BernardisFBertiFGalliCNorelliFBellucciCPolonelliLCostantinoPRappuoliRCassoneA. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med2005; 202: 597–606.
144.
PaulovicovaLPaulovicovaEKarelinAATsvetkovYENifantievNEBystrickyS. Humoral and cell-mediated immunity following vaccination with synthetic Candida cell wall mannan derived heptamannoside-protein conjugate: immunomodulatory properties of heptamannoside-BSA conjugate. Int Immunopharmacol2012; 14: 179–87.
145.
StefanettiGHuQ-YUseraARobinsonZAllanMSinghAImaseHCobbJZhaiHQuinnDLeiMSaulAAdamoRMacLennanCAMicoliF. Sugar-protein connectivity impacts on the immunogenicity of site-selective Salmonella O-antigen glycoconjugate vaccines. Angew Chem Int Ed2015; 54: 13198–203.
146.
AvciFYLiXTsujiMKasperDL. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med2011; 17: 1602–9.
